Inovio Pharmaceuticals (NYSE:INO) was downgraded by analysts at Aegis from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Stock Ratings Network reports. The analysts noted that the move was a valuation call.
Inovio Pharmaceuticals (NYSE:INO) opened at 1.59 on Friday. Inovio Pharmaceuticals has a one year low of $0.44 and a one year high of $3.03. The stock has a 50-day moving average of $1.43 and a 200-day moving average of $0.89. The company’s market cap is $287.6 million.
A number of other firms have also recently commented on INO. Analysts at Maxim Group raised their price target on shares of Inovio Pharmaceuticals from $1.00 to $2.00 in a research note to investors on Tuesday, July 9th. They now have a “buy” rating on the stock. Analysts at Zacks downgraded shares of Inovio Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, June 19th. They now have a $0.70 price target on the stock.
Inovio Pharmaceuticals, Inc, formerly Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of vaccines, called deoxyribonucleic acid (NYSE:INO) vaccines, focused on cancers and infectious diseases.